3/28
08:20 am
svra
Savara Inc (NASDAQ: SVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
Savara Inc (NASDAQ: SVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
3/27
07:05 am
svra
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
Medium
Report
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
3/26
04:45 pm
svra
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital
Low
Report
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital
3/26
04:29 pm
svra
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) [Yahoo! Finance]
Low
Report
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) [Yahoo! Finance]
3/26
04:05 pm
svra
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Low
Report
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
3/17
08:05 am
svra
Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025
Low
Report
Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025
3/6
08:45 am
svra
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) [Yahoo! Finance]
Medium
Report
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) [Yahoo! Finance]
3/6
08:05 am
svra
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Low
Report
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
3/3
04:42 pm
svra
Savara Announces Participation in the Leerink Global Healthcare Conference [Yahoo! Finance]
Medium
Report
Savara Announces Participation in the Leerink Global Healthcare Conference [Yahoo! Finance]
3/3
04:15 pm
svra
Savara Announces Participation in the Leerink Global Healthcare Conference
Medium
Report
Savara Announces Participation in the Leerink Global Healthcare Conference
2/14
04:05 pm
svra
Savara Announces New Employment Inducement Grant
Low
Report
Savara Announces New Employment Inducement Grant
2/8
09:44 pm
svra
Positive Signs As Multiple Insiders Buy Savara Stock [Yahoo! Finance]
Low
Report
Positive Signs As Multiple Insiders Buy Savara Stock [Yahoo! Finance]
1/30
08:39 am
svra
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research
Medium
Report
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research
1/29
04:05 pm
svra
Savara Announces Participation in Upcoming Healthcare Investor Conferences
Medium
Report
Savara Announces Participation in Upcoming Healthcare Investor Conferences